Insomnia Therapeutics Market Analysis By Treatment Type [Devices, Drugs (Benzodiazepines, Nonbenzodiazepines, Antidepressants, Orexin Antagonists, Melatonin Antagonists)], By Sales Channel, And Segment Forecasts, 2014 - 2025

  • ID: 4429695
  • Report
  • Region: Global
  • 101 pages
  • Grand View Research
1 of 4

FEATURED COMPANIES

  • Ebb Therapeutics.
  • Merck & Co.
  • Mylan N.V.
  • Pfizer Inc.
  • Sanofi S.A.
  • MORE

The global insomnia therapeutics market is expected to reach USD 3.45billion by 2025, according to a new report. The market is primarily driven by the presence of patented molecules, potential clinical pipeline candidates, rising stress level and increase in geriatric population who find it difficult to fall asleep. Increase in prevalence of insomnia &awareness about this condition and availability of safer drugs are anticipated to fuel revenue growth.

Insomnia is estimated to affect approximately 35% of the global population. Different patterns of the condition include difficulty in sleep initiation and maintenance, which is generally accompanied with frequent awakenings & awakening too early with trouble sleeping again. Long-term insomnia can hamper everyday life, which may result in non-productive work hours. If left untreated, this condition may lead to severe depression and nervous breakdown of the patient.

Factors influencing insomnia therapeutics market growth include rising stress level, presence of patented molecules in the market, potential drugs in clinical pipeline, introduction of technologically advanced medical devices, and growing geriatric population. Growing awareness about the impact of sleep deprivation on everyday life is anticipated to increase adoption rate of various treatments for insomnia, which is expected to lead to revenue growth of the insomnia therapeutics market.

Currently, widely adopted treatment options for insomnia include generic non benzodiazepines and antidepressants even though other novel agents such as orexin antagonists and melatonin antagonists are available in the market. Launch of Eisai’s Lemborexant is expected to cater to unmet medical needs in this segment and fuel growth of this market over the forecast period. According to United Nations (UN) report in 2015, population in the age group of 60 years and above is projected to grow by 56% and is expected to reach around 1.4 billion by 2030. These statistics indicate the growing geriatric population. Since this population base is more susceptible to sleep deprivation, the demand for insomnia therapeutics is anticipated to increase.

Further Key Findings From the Report Suggest:

  • North America held majority of the share in 2016 due to increase in awareness about diseases, growing geriatric population, and high adoption of therapeutics for treatment.
  • The U.S. dominated North America owing to the presence of largest sleep-deprived population and use of patented drugs for treatment.
  • Japan is the second largest market after the U.S. Asia Pacific is expected to be the fastest growing market due to the presence of emerging economies like China & India and launch of new drugs.
  • Some of the key players are Takeda Pharmaceutical Co. Ltd.; Vanda Pharmaceuticals; Merck & Co, Inc.; Pfizer Inc.; Teva Pharmaceutical Industries Ltd.; Mylan N. V.; Sumitomo Dainippon Pharma Co., Ltd.; Sanofi; Paratek Pharmaceuticals; and Ebb Therapeutics.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Ebb Therapeutics.
  • Merck & Co.
  • Mylan N.V.
  • Pfizer Inc.
  • Sanofi S.A.
  • MORE
1. Research Methodology
1.1 Information Procurement
1.1.1 Purchased database:
1.1.2 Internal database
1.2 Primary Research:
1.2.1 List of primary sources include:

2 Executive Summary
2.1 Market Snapshot

3 Insomnia Therapeutics Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.1.1 Market driver analysis
3.1.1.1 Technological advances in medical devices for insomnia.
3.1.1.2 Presence of potential clinical pipeline candidates for insomnia.
3.1.1.3 Rising stress levels and changing dynamics.
3.1.2 Market restraint analysis
3.1.2.1 Lower diagnosis rate, low treatment rate and high number of dis-satisfied patients.
3.1.2.2 Declining revenues with the expiry of branded drugs.
3.2 Insomnia Therapeutics Market - SWOT Analysis, by Factor (political & legal, economic and technological)
3.3 Industry Analysis - Porter’s

4 Insomnia Therapeutics Market: Treatment Type Estimates & Trend Analysis
4.1 Global Insomnia Therapeutics Market: Treatment Type Analysis
4.2 Drugs
4.2.1 Drugs treatment type market estimates and forecasts, 2014 - 2025 (USD Million)
4.3 Devices
4.3.1 Devices treatment type market estimates and forecasts, 2014 - 2025 (USD Million)

5 Insomnia Therapeutics: Sales Channel Type Estimates & Trend Analysis
5.1 Global Insomnia Therapeutics Market: Sales Channel Type Analysis
5.2 Prescription
5.2.1 Prescription sales channel segment market estimates and forecasts, 2014 - 2025 (USD Million)
5.3 Over-the-Counter (OTC)
5.3.1 Over-the-Counter (OTC) sales channel segment market estimates and forecasts, 2014 - 2025 (USD Million)

6 Insomnia Therapeutics Market: Regional Estimates & Trend Analysis, by Treatment Type & Sales Channel
6.1 Global Insomnia Therapeutics Market Share, by Region, 2015 & 2025
6.2 North America
6.2.1 Market estimates and forecasts, by treatment type 2014 - 2025 (USD Million)
6.2.2 Market estimates and forecasts, by sales channel 2014 - 2025 (USD Million
6.2.3 U.S.
6.2.3.1 Market estimates and forecasts, by treatment type 2014 - 2025 (USD Million)
6.2.3.2 Market estimates and forecasts, by sales channel 2014 - 2025 (USD Million)
6.2.4 Canada
6.2.4.1 Market estimates and forecasts, by treatment type 2014 - 2025 (USD Million)
6.2.4.2 Market estimates and forecasts, by sales channel 2014 - 2025 (USD Million)
6.3 Europe
6.3.1 Market estimates and forecasts, by treatment type 2014 - 2025 (USD Million)
6.3.2 Market estimates and forecasts, by sales channel 2014 - 2025 (USD Million)
6.3.3 Germany
6.3.3.1 Market estimates and forecasts, by treatment type 2014 - 2025 (USD Million)
6.3.3.2 Market estimates and forecasts, by sales channel 2014 - 2025 (USD Million)
6.3.4 UK
6.3.4.1 Market estimates and forecasts, by treatment type 2014 - 2025 (USD Million)
6.3.4.2 Market estimates and forecasts, by sales channel 2014 - 2025 (USD Million)
6.4 Asia Pacific
6.4.1 Market estimates and forecasts, by treatment type 2014 - 2025 (USD Million)
6.4.2 Market estimates and forecasts, by sales channel 2014 - 2025 (USD Million)
6.4.3 Japan
6.4.3.1 Market estimates and forecasts, by treatment type 2014 - 2025 (USD Million)
6.4.3.2 Market estimates and forecasts, by sales channel 2014 - 2025 (USD Million)
6.4.4 China
6.4.4.1 Market estimates and forecasts, by treatment type 2014 - 2025 (USD Million)
6.4.4.2 Market estimates and forecasts, by sales channel 2014 - 2025 (USD Million)
6.5 Latin America
6.5.1 Market estimates and forecasts, by treatment type 2014 - 2025 (USD Million)
6.5.2 Market estimates and forecasts, by sales channel 2014 - 2025 (USD Million)
6.5.3 Brazil
6.5.3.1 Market estimates and forecasts, by treatment type 2014 - 2025 (USD Million)
6.5.3.1 Market estimates and forecasts, by sales channel 2014 - 2025 (USD Million)
6.5.4 Mexico
6.5.4.1 Market estimates and forecasts, by treatment type 2014 - 2025 (USD Million)
6.5.4.2 Market estimates and forecasts, by sales channel 2014 - 2025 (USD Million)
6.6 MEA
6.6.1 Market estimates and forecasts, by treatment type 2014 - 2025 (USD Million)
6.6.2 Market estimates and forecasts, by sales channel 2014 - 2025 (USD Million)
6.6.3 South Africa
6.2.3.1 Market estimates and forecasts, by treatment type 2014 - 2025 (USD Million)
6.2.3.2 Market estimates and forecasts, by sales channel 2014 - 2025 (USD Million)

7 Competitive Landscape
7.1 Company Profiles
7.1.1 Takeda Pharmaceutical Company Ltd.
7.1.1.1 Company overview
7.1.1.2 Financial performance
7.1.1.3 Product Benchmarking
7.1.1.4 Strategic initiatives
7.1.2 Vanda Pharmaceuticals Inc.
7.1.2.1 Company overview
7.1.2.2 Financial performance
7.1.2.3 Product benchmarking
7.1.2.4 Strategic initiatives
7.1.3 Merck & Co.
7.1.3.1 Company overview
7.1.3.2 Financial performance
7.1.3.3 Product Benchmarking
7.1.3.4 Strategic initiatives
7.1.4 Mylan N.V.
7.1.4.1 Company overview
7.1.4.2 Financial performance
7.1.4.3 Product Benchmarking
7.1.4.4 Strategic initiatives
7.1.5 Pfizer Inc.
7.1.5.1 Company overview
7.1.5.2 Financial performance
7.1.5.3 Product Benchmarking
7.1.5.4 Strategic initiatives
7.1.6 Teva Pharmaceutical Industries Ltd.
7.1.6.1 Company overview
7.1.6.2 Financial performance
7.1.6.3 Product Benchmarking
7.1.6.4 Strategic initiatives
7.1.7 Sumitomo Dainippon Pharma Co., Ltd.
7.1.7.1 Company overview
7.1.7.2 Financial performance
7.1.7.3 Product Benchmarking
7.1.7.4 Strategic initiatives
7.1.8 Sanofi S.A.
7.1.8.1 Company overview
7.1.8.2 Financial performance
7.1.8.3 Product Benchmarking
7.1.8.4 Strategic initiatives
7.1.9 Paratek Pharmaceuticals, Inc.
7.1.9.1 Company overview
7.1.9.2 Financial performance
7.1.9.3 Product Benchmarking
7.1.9.4 Strategic initiatives
7.1.10 Ebb Therapeutics.
7.1.10.1 Company overview
7.1.10.2 Product Benchmarking
7.1.10.3 Strategic initiatives

List of Tables:
Table 1 Global insomnia therapeutics market estimates and forecast by treatment type, 2014 - 2025 (USD Million)
Table 2 Global insomnia therapeutics market estimates and forecast by sales channel, 2014 - 2025 (USD Million)
Table 3 North America insomnia therapeutics market estimates and forecast by treatment type, 2014 - 2025 (USD Million)
Table 4 North America insomnia therapeutics market estimates and forecast by sales channel, 2014 - 2025 (USD Million)
Table 5 U.S. insomnia therapeutics market estimates and forecast by treatment type, 2014 - 2025 (USD Million)
Table 6 U.S. insomnia therapeutics market estimates and forecast by sales channel, 2014 - 2025 (USD Million)
Table 7 Canada insomnia therapeutics market estimates and forecast by treatment type, 2014 - 2025 (USD Million)
Table 8 Canada insomnia therapeutics market estimates and forecast by sales channel, 2014 - 2025 (USD Million)
Table 9 Latin America insomnia therapeutics market estimates and forecast by treatment type, 2014 - 2025 (USD Million)
Table 10 Latin America insomnia therapeutics market estimates and forecast by sales channel, 2014 - 2025 (USD Million)
Table 11 Mexico insomnia therapeutics market estimates and forecast by treatment type, 2014 - 2025 (USD Million)
Table 12 Mexico insomnia therapeutics market estimates and forecast by sales channel, 2014 - 2025 (USD Million)
Table 13 Brazil insomnia therapeutics market estimates and forecast by treatment type, 2014 - 2025 (USD Million)
Table 14 Brazil insomnia therapeutics market estimates and forecast by sales channel, 2014 - 2025 (USD Million)
Table 15 Europe insomnia therapeutics market estimates and forecast by treatment type, 2014 - 2025 (USD Million)
Table 16 Europe insomnia therapeutics market estimates and forecast by sales channel, 2014 - 2025 (USD Million)
Table 17 U.K. insomnia therapeutics market estimates and forecast by treatment type, 2014 - 2025 (USD Million)
Table 18 U.K. insomnia therapeutics market estimates and forecast by sales channel, 2014 - 2025 (USD Million)
Table 19 Germany insomnia therapeutics market estimates and forecast by treatment type, 2014 - 2025 (USD Million)
Table 20 Germany insomnia therapeutics market estimates and forecast by sales channel, 2014 - 2025 (USD Million)
Table 21 Asia Pacific insomnia therapeutics market estimates and forecast by treatment type, 2014 - 2025 (USD Million)
Table 22 Asia Pacific insomnia therapeutics market estimates and forecast by sales channel, 2014 - 2025 (USD Million)
Table 23 Japan insomnia therapeutics market estimates and forecast by treatment type, 2014 - 2025 (USD Million)
Table 24 Japan insomnia therapeutics market estimates and forecast by application, 2014 - 2025 (USD Million)
Table 25 China insomnia therapeutics market estimates and forecast by treatment type, 2014 - 2025 (USD Million)
Table 26 China insomnia therapeutics market estimates and forecast by sales channel, 2014 - 2025 (USD Million)
Table 27 MEA insomnia therapeutics market estimates and forecast by treatment type, 2014 - 2025 (USD Million)
Table 28 MEA insomnia therapeutics market estimates and forecast by sales channel, 2014 - 2025 (USD Million)
Table 29 South Africa insomnia therapeutics market estimates and forecast by treatment type, 2014 - 2025 (USD Million)
Table 30 South Africa insomnia therapeutics market estimates and forecast by sales channel, 2014 - 2025 (USD Million)

List of Figures:
Figure 1 Market research process
Figure 2 Information procurement
Figure 3 Primary research pattern
Figure 4 Market summary
Figure 5 Market trends & outlook
Figure 6 Market segmentation & scope
Figure 7 Market driver relevance analysis (Current & future impact)
Figure 8 Market restraint relevance analysis (Current & future impact)
Figure 9 Key opportunity priorities
Figure 10 SWOT analysis, by factor (political & legal, economic and technological)
Figure 11 Porter’s Five Forces Analysis
Figure 12 Global insomnia therapeutics market, Heat map analysis
Figure 13 Global insomnia therapeutics market treatment type outlook & key takeaways
Figure 14 Global insomnia therapeutics market drugs segment outlook & key takeaways
Figure 15 Global insomnia therapeutics market devices segment outlook & key takeaways
Figure 16 Global insomnia therapeutics market: sales channel type outlook & key takeaways
Figure 17 Global insomnia therapeutics market, regional outlook & key takeaways 2014 - 2025
Figure 18 North America insomnia therapeutics estimates and forecasts, 2014 - 2025 (USD Million)
Figure 19 U.S. insomnia therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
Figure 20 Canada insomnia therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
Figure 21 Europe insomnia therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
Figure 22 Germany insomnia therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
Figure 23 U.K. insomnia therapeutics estimates and forecasts, 2014 - 2025 (USD Million)
Figure 24 Asia Pacific insomnia therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
Figure 25 China insomnia therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
Figure 26 Japan insomnia therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
Figure 27 Latin America insomnia therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
Figure 28 Brazil insomnia therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
Figure 29 Mexico insomnia therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
Figure 30 MEA insomnia therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
Figure 31 South Africa insomnia therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Takeda Pharmaceutical Company Ltd.
  • Vanda Pharmaceuticals Inc.
  • Merck & Co.
  • Mylan N.V.
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Sanofi S.A.
  • Paratek Pharmaceuticals, Inc.
  • Ebb Therapeutics.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll